Medication info
Tugenumon 5/8 milligrams

Tugenumon 5/8 milligrams

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tabletCandesartan Cilexetil›8mg / 1 tablet
Manufacturer / importer
Dong-A ST Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets (10 tablets/PTP x 3)
Approval status
Active

MFDS item code 201702411 · Approved 2017.05.16 · Insurance code 642507400

Summary

Main use
Treatment of hypertension and heart failure, improvement of dyslipidemia, and suppression of the progression of atherosclerosis and cardiovascular risk
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: For patients at increased risk of hypotension, such as those with volume depletion, administer an initial dose of 4 mg with careful monitoring. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of 2 weeks or more, up to a maximum of 32 mg once daily, depending on the patient's tolerability. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medicine at a dose of 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
Child dose
The safety and efficacy of this medicine have not been established in adolescents and children 18 years of age or younger. The safety and efficacy of this medicine have not been established in adolescents and children 18 years of age or younger.

Ingredients

Manufacturer
Dong-A ST Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure, improvement of dyslipidemia, and suppression of the progression of atherosclerosis and cardiovascular risk

  • Essential hypertension
  • heart failure
  • left ventricular systolic dysfunction
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • family history of premature coronary heart disease
View approved original text

This medication is used for patients who need to take candesartan cilexetil and rosuvastatin simultaneously. Candesartan cilexetil is mainly used as additional or alternative therapy for patients with essential hypertension and heart failure with left ventricular dysfunction. Rosuvastatin is used as an adjunct to diet for patients with dyslipidemia such as hypercholesterolemia and mixed dyslipidemia, and is also helpful for patients with homozygous familial hypercholesterolemia. Additionally, it lowers blood cholesterol and LDL-cholesterol levels, delaying the progression of atherosclerosis, and is used in patients with primary dysbetalipoproteinemia. Moreover, it helps reduce the risk of stroke, myocardial infarction, and revascularization in high-risk cardiovascular disease patients with elevated high-sensitivity C-reactive protein levels. Therefore, this medication is used for the prevention and treatment of cardiovascular disease through blood pressure control and dyslipidemia improvement.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: For patients at increased risk of hypotension, such as those with volume depletion, administer an initial dose of 4 mg with careful monitoring. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of 2 weeks or more, up to a maximum of 32 mg once daily, depending on the patient's tolerability. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medicine at a dose of 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Child dose

The safety and efficacy of this medicine have not been established in adolescents and children 18 years of age or younger. The safety and efficacy of this medicine have not been established in adolescents and children 18 years of age or younger.

Precautions

This medication can cause serious harm to the fetus and newborn, especially during pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. It should not be used in patients with allergies to this medication, severe liver dysfunction, women who are pregnant or breastfeeding, and patients with certain kidney diseases. Elderly patients, patients with high serum potassium levels, and those with weakened liver or kidney function should use this medication cautiously and require regular examinations. If muscle pain, muscle weakness, or unusual muscle symptoms occur while taking this medication, consult a doctor immediately, and if necessary, a blood test should be conducted to check for muscle damage. If liver dysfunction is suspected, the use of this medication should also be discontinued and a doctor's opinion sought, with regular testing of liver enzyme levels recommended. This medication may interact with other drugs, so it is essential to inform healthcare providers of any other medications being taken, especially when used concurrently with potassium-sparing diuretics or certain antibiotics and antifungals. Women who are pregnant or planning to become pregnant should consult with healthcare providers before taking this medication and use appropriate contraceptive methods. The safety and efficacy in children and adolescents have not been established, so this medication should not be used in these populations. In cases of overdose, seek medical attention promptly for appropriate treatment, as symptoms such as hypotension or dizziness may occur. During treatment, rapid drops in blood pressure may happen, so caution is needed when driving or operating machinery. Keep this medication out of the reach of children, and do not transfer medications to other containers.

Side effects

Headache, nasopharyngitis, local infection, fatigue, systemic itching, dermatitis, itching, joint stiffness, limb pain, glare, dyspepsia, miliary, periodontitis, musculoskeletal pain, neck pain, nausea, hyperglycemia, hyponatremia, hand fractures, hypoglycemia, nephrolithiasis, cough, tooth extraction, chest discomfort, dizziness, positional vertigo, itching, nausea, paralysis, tension increase, syncope, facial flushing, weight gain, facial edema, thirst, sleep disturbances, decreased libido, forgetfulness, anorexia, increased appetite, tinnitus, dysgeusia, erectile dysfunction, angioedema, constipation, abdominal pain, pancreatitis, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction syndrome with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, insomnia, nightmares, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, impaired memory, amnesia, memory disturbance, confusion, severe muscle weakness, ocular myasthenia, hypotension, hyperkalemia, renal impairment, increased creatinine, increased urea, increased potassium, decreased sodium, increased ALT, increased AST, increased γ-GTP, liver function disorder, jaundice, blood and lymphatic system disorders, leukopenia, neutropenia, agranulocytosis, fatigue, hunger, sweating, hand tremors, decreased concentration, convulsions, consciousness disturbance, intestinal vascular edema, diarrhea, hepatitis, rash, urticaria, angioedema, myalgia, fatigue, increased creatine kinase, increased myoglobin in blood and urine, rhabdomyolysis, arthralgia, myalgia, low back pain, renal impairment, acute renal failure, interstitial pneumonia, shock, syncope, loss of consciousness, polyneuropathy, amnesia, peripheral neuropathy, dyspnea, intestinal vascular edema, nausea, abdominal pain, diarrhea, increased liver enzymes, hepatitis, jaundice, rash, urticaria, angioedema, myalgia, myopathy, rhabdomyolysis, renal impairment, acute renal failure, interstitial lung disease, jaundice, hepatitis, increased transaminase, Stevens-Johnson syndrome, drug reaction syndrome with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbances, insomnia, nightmares, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, impaired memory, amnesia, memory disturbance, confusion, severe muscle weakness, ocular myasthenia, hypotension, hyperkalemia, renal impairment, increased creatinine, increased urea, increased potassium, decreased sodium, increased ALT, myalgia, increased CK, dizziness, constipation, increased AST, weakness, joint pain, fatigue, numbness, dysesthesia, chest discomfort, nausea, abdominal pain, diarrhea, anorexia, abdominal distension, itching, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, acute renal failure, oliguria, thrombocytopenia, increased serum creatinine

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. The recommended storage temperature is between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets (10 tablets/PTP x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.